search icon
  • Print
  • ShareThis
  • Text Size


In order to add a post to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.

 

Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.


RSS Feed Print Category View
More Drugs Show Promise in Fighting Hepatitis C - HealthDay Article
ThomasKim
Posted: Thursday, August 15, 2013 11:36 AM
Joined: 2/20/2013
Posts: 38


More Drugs Show Promise in Fighting Hepatitis C
Faldaprevir and deleobuvir are part of effort to develop treatments that avoid harsh side effects

 

An experimental drug duo may cure some cases of the liver disease hepatitis C, without the severe side effects of standard therapy, a new clinical trial suggests.

The study, of 362 people with chronic hepatitis C, found that the new drugs -- combined with one older drug -- cleared the virus from up to 69 percent of patients. And that was without having to use interferon, a difficult-to-take injection drug that is part of the current therapy.

Experts said the findings, published in the Aug. 15 issue of the New England Journal of Medicine, are another step forward in vastly improving hepatitis C treatment.

Dozens of drugs are in development, and some are currently being considered for approval by the U.S. Food and Drug Administration (FDA).

"These are very exciting times in hepatitis C treatment," said Dr. Michael Saag, an infectious disease specialist at the University of Alabama at Birmingham who was not involved in the new study.

 

To read the full article, please visit: http://consumer.healthday.com/cancer-information-5/mis-cancer-news-102/experimental-drugs-may-cure-some-hepatitis-c-cases-679239.html



 

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site